WilmerHale Counsels Exonics Therapeutics in $5M Seed Financing
Exonics Therapeutics, Inc., a newly formed biotechnology company focused on developing gene editing technologies to permanently correct a majority of mutations causing Duchenne muscular dystrophy and other neuromuscular diseases, announced a commitment of $5 million in seed financing from CureDuchenne Ventures. The initial seed funding will allow Exonics to advance the preclinical research of its Scientific Founder and Chief Science Advisor Eric Olson, PhD.
The WilmerHale team representing Exonics Therapeutics was led by Gary Schall.
Read Exonics Therapeutics' press release for more information.